Squar Milner Financial Services’s Nektar Therapeutics NKTR Stock Holding History

Squar Milner Financial Services’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-27	Closed	-$7K	–	524
2020 Q1	$7K	Hold	27	–	–	﹤0.01%	574
2019 Q4	$8K	Buy	+27	New	+$7.83K	﹤0.01%	602
2019 Q3	–	Sell	-19	Closed	-$10K	–	538
2019 Q2	$10K	Hold	19	–	–	0.01%	522
2019 Q1	$9K	Hold	19	–	–	0.01%	545
2018 Q4	$9K	Hold	19	–	–	0.01%	485
2018 Q3	$17K	Hold	19	–	–	0.02%	431
2018 Q2	$14K	Buy	+19	New	+$21.9K	0.01%	531

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Squar Milner Financial Services's NKTR Position: Q2 2020 in Review

Squar Milner Financial Services sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 27 shares — an estimated $7K sold.

Squar Milner Financial Services first reported a position in NKTR in Q2 2018 and held it in 7 quarters. The position peaked at $17K in Q3 2018. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

Squar Milner Financial Services reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
Squar Milner Financial Services sold 27 Nektar Therapeutics shares in Q2 2020, an estimated $7K.
Squar Milner Financial Services first reported a position in Nektar Therapeutics in Q2 2018 and held it in 7 quarters.
Squar Milner Financial Services's Nektar Therapeutics position peaked at $17K in Q3 2018.
260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on Squar Milner Financial Services's 13F filing for Q2 2020, filed 16 Jul 2020.